{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P10265",
      "entity_text" : "protease",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5460479",
      "entity_text" : "AT",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "We anticipated that emicizumab would be unlikely to interfere with the actions of AT or TFPI, because emicizumab binds the epidermal growth factor (EGF)-like domains of FIXa and FXa, while AT and TFPI bind the protease domains, and because its binding affinities are on the order of 1 micromolar.",
  "reading_complete" : "2020-08-03T12:56:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T12:54:35Z",
  "trigger" : "bind",
  "evidence" : [ "AT and TFPI bind the protease" ],
  "pmc_id" : "6524866",
  "score" : 0
}